Tenon Medical shareholders approve warrant exercisability and equity plan increase at 2025 annual meeting

Tenon Medical, Inc.

All seven director nominees elected: Ferrari, Foster, Ginn, Hochschuler, Howard, Jacques, Weigle each received >2.48M votes for.
Approved exercisability of Series C-1 (up to 2,445,700 shares) and C-2 (up to 1,222,850 shares) warrants at $1.25/share; 2,517,314 for, 120,940 against.
2022 Equity Incentive Plan amendments approved: share reserve increased from 189,870 to 1,328,365 shares; evergreen provision modified to up to 4% outstanding annually.
Ratified Haskell & White LLP as independent auditor for FY2025 with 4,488,067 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.